Roche Holding AG (RHHVF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Roche Holding AG (RHHVF) trades at $410.81 with AI Score 54/100 (Grade B). Roche Holding AG is a global healthcare company operating in pharmaceuticals and diagnostics. Market cap: $283B, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 15, 2026RHHVF stock analysis for 2026: Analysts have set a consensus price target of $470.09 for Roche Holding AG, suggesting 14.4% upside from the current price of $410.81. The AI MoonshotScore is 54/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
RHHVF: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Roche Holding AG (RHHVF) Healthcare & Pipeline Overview
Roche Holding AG, a Swiss multinational healthcare company, operates in pharmaceuticals and diagnostics, offering a diverse portfolio of products for oncology, immunology, and infectious diseases. With a strong focus on research and development and a global presence, Roche competes with major pharmaceutical companies in a rapidly evolving healthcare landscape.
What Is the Investment Thesis for RHHVF?
Roche Holding AG presents a compelling investment case based on its diversified healthcare portfolio and strong market position. With a market capitalization of $283B and a profit margin of 20.9%, Roche demonstrates financial stability. The company's dividend yield of 3.06% offers an attractive return for investors. Growth catalysts include expansion in key therapeutic areas like oncology and immunology, as well as advancements in diagnostic technologies. However, potential risks include regulatory challenges, competition from other pharmaceutical giants, and the inherent uncertainty in drug development. The company's beta of 0.21 suggests relatively low volatility compared to the overall market.
Based on FMP financials and quantitative analysis
RHHVF Key Highlights
- Market Cap of $283B reflects Roche's significant presence in the healthcare industry.
- P/E ratio of 20.8 indicates the price investors are willing to pay for each dollar of Roche's earnings.
- Profit Margin of 20.9% demonstrates Roche's efficiency in converting revenue into profit.
- Gross Margin of 73.5% showcases Roche's ability to manage production costs effectively.
- Dividend Yield of 3.06% provides a steady income stream for investors.
Who Are RHHVF's Competitors?
RHHVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALPMF Astellas Pharma Inc. | $14.50 | +6.03% | $26.0B | 58 |
| AZN AstraZeneca PLC | $164.52 | -2.59% | $127B | 61 |
| AZNCF AstraZeneca PLC | $189.90 | -1.35% | $294B | 60 |
| BAYRY Bayer AG | $13.43 | -2.68% | $52.8B | 51 |
| BMY Bristol-Myers Squibb Company | $60.16 | -0.95% | $123B | 89 |
| NVSEF Novartis AG | $153.00 | +0.73% | $292B | 55 |
| NVS Novartis AG | $152.65 | -0.72% | $292B | 57 |
| MRK Merck & Co., Inc. | $124.41 | -2.42% | $307B | 85 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RHHVF's Key Strengths?
- Diversified product portfolio in pharmaceuticals and diagnostics
- Strong research and development capabilities
- Global presence and distribution network
- High profit margin and financial stability
What Are RHHVF's Weaknesses?
- Dependence on key products and patents
- Exposure to regulatory risks and patent expirations
- Competition from other pharmaceutical and diagnostics companies
- Potential for product recalls and liability claims
What Could Drive RHHVF Stock Higher?
- Potential FDA approvals for new pharmaceutical products in oncology and immunology.
- Expansion of diagnostic testing capabilities for infectious diseases.
- Strategic collaborations with other companies and research institutions.
- Publication of clinical trial results for novel therapies.
- Growth in emerging markets and personalized medicine.
What Are the Key Risks for RHHVF?
- Regulatory challenges and delays in drug approvals.
- Competition from generic drugs and other pharmaceutical companies.
- Patent expirations and loss of exclusivity for key products.
- Economic downturns and healthcare reforms.
- Product recalls and liability claims.
What Are the Growth Opportunities for RHHVF?
- Expansion in Oncology: Roche has a significant presence in the oncology market, which is expected to continue growing due to the increasing incidence of cancer globally. By developing and commercializing new cancer therapies, Roche can capitalize on this growth opportunity. The global oncology market is projected to reach $300 billion by 2028.
- Advancements in Diagnostics: The diagnostics market is driven by technological advancements and the need for accurate and timely disease detection. Roche can leverage its expertise in diagnostics to develop innovative solutions for various diseases, including infectious diseases and cardiovascular conditions. The global diagnostics market is expected to reach $120 billion by 2027.
- Strategic Collaborations: Roche can pursue strategic collaborations with other companies and research institutions to expand its product portfolio and access new technologies. The research collaboration agreement with Synlogic, Inc. for the treatment of inflammatory bowel disease (IBD) exemplifies this approach. These collaborations can accelerate the development of innovative therapies and diagnostic solutions.
- Emerging Markets: Roche can expand its presence in emerging markets, where there is a growing demand for healthcare products and services. By tailoring its products and services to meet the specific needs of these markets, Roche can tap into new growth opportunities. Emerging markets are expected to contribute significantly to the growth of the global healthcare industry.
- Personalized Medicine: The rise of personalized medicine presents a significant growth opportunity for Roche. By developing diagnostic tests that can identify patients who are most likely to benefit from specific therapies, Roche can improve treatment outcomes and reduce healthcare costs. Personalized medicine is expected to revolutionize the healthcare industry.
What Opportunities Does RHHVF Have?
- Expansion in emerging markets
- Development of personalized medicine solutions
- Strategic collaborations and acquisitions
- Growth in the diagnostics market
What Threats Does RHHVF Face?
- Increasing competition from generic drugs
- Stringent regulatory requirements and pricing pressures
- Economic downturns and healthcare reforms
- Technological disruptions and cybersecurity threats
What Are RHHVF's Competitive Advantages?
- Strong brand reputation
- Extensive patent portfolio
- Global distribution network
- Expertise in both pharmaceuticals and diagnostics
- High barriers to entry in the pharmaceutical and diagnostics industries
What Does RHHVF Do?
Founded in 1896 in Basel, Switzerland, by Fritz Hoffmann-La Roche, Roche Holding AG initially focused on producing standardized pharmaceuticals. Over the decades, Roche has evolved into a global leader in both pharmaceuticals and diagnostics. The company's pharmaceutical division develops and markets drugs for various therapeutic areas, including oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune conditions, and transplantation. Key products include treatments for cancer, multiple sclerosis, and influenza. Roche's diagnostics division provides in vitro tests for diagnosing diseases such as cancer, cardiovascular conditions, diabetes, COVID-19, hepatitis, and human papillomavirus. This division also supplies diagnostic instruments and reagents to hospitals, laboratories, and point-of-care settings. Roche operates in Switzerland, Germany, the United States, and internationally, maintaining a significant global presence through subsidiaries and partnerships. The company's research and development efforts are central to its strategy, with ongoing investments in innovative therapies and diagnostic solutions. Roche has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD).
What Products and Services Does RHHVF Offer?
- Develops and markets pharmaceutical products for various therapeutic areas.
- Offers in vitro tests for the diagnosis of various diseases.
- Supplies diagnostic instruments and reagents to hospitals and laboratories.
- Conducts research and development to discover new therapies and diagnostic solutions.
- Collaborates with other companies and research institutions to expand its product portfolio.
- Operates in Switzerland, Germany, the United States, and internationally.
How Does RHHVF Make Money?
- Develops and commercializes pharmaceutical products.
- Manufactures and sells diagnostic instruments and reagents.
- Provides diagnostic testing services.
- Generates revenue through product sales and service fees.
What Industry Does RHHVF Operate In?
Roche Holding AG operates in the highly competitive pharmaceutical and diagnostics industry. The global pharmaceutical market is characterized by intense research and development, stringent regulatory requirements, and patent protection. Key trends include the rise of personalized medicine, the increasing prevalence of chronic diseases, and the growing demand for diagnostic testing. Roche competes with major pharmaceutical companies such as AstraZeneca (AZN) and Bayer (BAYRY). The diagnostics market is driven by technological advancements and the need for accurate and timely disease detection.
Who Are RHHVF's Key Customers?
- Hospitals and clinics
- Laboratories
- Patients
- Healthcare providers
- Research institutions
FY2026 estForward Outlook
Wall Street analysts project Roche Holding AG revenue of about $61.48B for fiscal 2026, with EPS near $19.63. The estimate reflects 15 contributing analysts.
F-Score 7/9Financial Health
Roche Holding AG's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 5.26 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 41%Key Financial Metrics
Return on equity for Roche Holding AG stands at 41.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 12.8%, showing how much profit it generates from its asset base. RHHVF trades at a trailing price-to-earnings ratio of 20.77, below the Healthcare sector average of ~23x. Its free cash flow yield is 4.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.38 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.9%, the inverse of the P/E and a quick read on earnings relative to price.
Roche Holding AG (RHHVF) Valuation Context
Valued at $283B, RHHVF is classified as a mega-cap stock. Relative to its peer group, RHHVF's quantitative score of 54/100 is roughly in line with the peer average of 64/100.
Company Profile
Roche Holding AG operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Basel, CH. The company is led by CEO Thomas Schinecker. RHHVF has traded publicly since 2009.
RHHVF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diversified product portfolio in pharmaceuticals and diagnostics
- Strong research and development capabilities
- Global presence and distribution network
- High profit margin and financial stability
Bear Case
- Dependence on key products and patents
- Exposure to regulatory risks and patent expirations
- Competition from other pharmaceutical and diagnostics companies
- Potential for product recalls and liability claims
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
RHHVF Latest News
-
Roche Launches AXELIOS 1, A Next-Generation Sequencing Platform Combining Accuracy, Speed, Scalability And Cost Efficiency For Research Laboratories
benzinga · Jun 29, 2026
-
Roche's Genentech Gets FDA sBLA Acceptance for Lunsumio VELO And Polivy Combination In Relapsed or Refractory Large B-Cell Lymphoma
benzinga · Jun 18, 2026
-
Roche's Phase III ATOMIC Study Drives FDA Priority Review For Tecentriq Plus Chemotherapy As Potential New Standard Of Care In Stage III dMMR/MSI-H Colon Cancer
benzinga · Jun 11, 2026
-
Roche's VENTANA MMR RxDx Panel Secures IVDR Approval As Companion Diagnostic Across Five Cancer Types, Six Indications For Keytruda, Imfinzi, Lynparza And Jemperli
benzinga · Jun 11, 2026
RHHVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RHHVF.
Price Targets
Consensus target: $470.09
RHHVF MoonshotScore
What does this score mean?
The MoonshotScore rates RHHVF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
Roche Launches AXELIOS 1, A Next-Generation Sequencing Platform Combining Accuracy, Speed, Scalability And Cost Efficiency For Research Laboratories
Roche's Genentech Gets FDA sBLA Acceptance for Lunsumio VELO And Polivy Combination In Relapsed or Refractory Large B-Cell Lymphoma
Roche's Phase III ATOMIC Study Drives FDA Priority Review For Tecentriq Plus Chemotherapy As Potential New Standard Of Care In Stage III dMMR/MSI-H Colon Cancer
Roche's VENTANA MMR RxDx Panel Secures IVDR Approval As Companion Diagnostic Across Five Cancer Types, Six Indications For Keytruda, Imfinzi, Lynparza And Jemperli
Leadership: Thomas Schinecker
CEO
Thomas Schinecker is the CEO of Roche Holding AG. His career within Roche spans several leadership roles, demonstrating a deep understanding of the company's operations and strategic direction. Prior to becoming CEO, he held key positions in the diagnostics division, contributing to its growth and innovation. His expertise lies in driving performance and fostering a culture of innovation within the organization. He is responsible for managing over 100,000 employees globally.
Track Record: Under Thomas Schinecker's leadership, Roche has continued to focus on innovation and strategic growth. Key achievements include navigating the evolving healthcare landscape and driving advancements in personalized medicine. His strategic decisions have contributed to the company's strong financial performance and market position. He continues to focus on driving growth in key therapeutic areas and diagnostic solutions.
RHHVF OTC Market Information
The OTC Other tier, where Roche Holding AG (RHHVF) trades, represents a segment of the over-the-counter (OTC) market with minimal listing requirements. Companies in this tier often do not meet the minimum financial standards required for listing on major exchanges like the NYSE or NASDAQ. This tier is generally considered to have the least stringent requirements compared to OTCQX and OTCQB, leading to potentially higher risks for investors due to less available information and oversight. Trading on the OTC Other tier does not necessarily indicate a company is illegitimate, but it signals a need for increased due diligence.
- OTC Tier: OTC Other
- Limited Information: OTC Other stocks often have limited financial disclosures, making it difficult to assess the company's financial health.
- Lower Liquidity: Reduced trading volume can lead to wider bid-ask spreads and increased price volatility.
- Regulatory Scrutiny: OTC stocks are subject to less regulatory oversight compared to exchange-listed stocks.
- Potential for Fraud: The OTC market has a higher risk of fraudulent schemes and scams.
- Price Volatility: OTC stocks can experience significant price swings due to lower trading volume and market manipulation.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Check for any legal or regulatory issues involving the company.
- Review the company's OTC Markets profile for disclosures and compliance.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC trading.
- Established Business: Roche Holding AG has a long history and a strong reputation in the healthcare industry.
- Global Operations: The company operates in multiple countries and has a significant global presence.
- Regulatory Compliance: Roche Holding AG is subject to regulatory oversight in various jurisdictions.
- Financial Stability: The company has a high market cap and a solid financial performance.
- Dividend Payments: Roche Holding AG pays dividends to its shareholders, indicating financial stability.
RHHVF Healthcare Stock FAQ
What does the AI Score mean for RHHVF?
RHHVF holds an AI Score of 54/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Roche Holding AG is a global healthcare company operating in pharmaceuticals and diagnostics. The company develops and markets pharmaceutical products and in-vitro diagnostic solutions for various …
What does Roche Holding AG do?
Roche Holding AG operates in two primary divisions: pharmaceuticals and diagnostics. The pharmaceutical division develops, manufactures, and markets prescription drugs for various therapeutic areas, including oncology, immunology, neuroscience, and infectious diseases. The diagnostics division provides in vitro diagnostic tests, instruments, and reagents for disease detection and monitoring. Roche's integrated approach to healthcare combines these two divisions to deliver personalized healthcare solutions to patients worldwide.
What do analysts say about RHHVF stock?
Analyst consensus on Roche Holding AG (RHHVF) is generally positive, reflecting the company's strong market position and diversified healthcare portfolio. Key valuation metrics, such as the P/E ratio and dividend yield, are closely monitored. Growth considerations include the company's ability to develop and commercialize new therapies and diagnostic solutions, as well as its expansion in emerging markets.
What are the main risks for RHHVF?
The main risks for Roche Holding AG (RHHVF) include regulatory challenges, competition from generic drugs and other pharmaceutical companies, patent expirations, and economic downturns. Regulatory risks involve potential delays or rejections in drug approvals, which can impact revenue and profitability. Competition from generic drugs can erode market share and pricing power.
What are the key factors to evaluate for RHHVF?
Roche Holding AG (RHHVF) holds an AI score of 54/100 (moderate). P/E: 20.8x vs the S&P 500's ~20-25x. Analysts target $470.09 (+14%). Not financial advice.
How frequently does RHHVF data refresh on this page?
RHHVF's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RHHVF's recent stock price performance?
Roche Holding AG (RHHVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio in pharmaceuticals and diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RHHVF overvalued or undervalued right now?
Roche Holding AG (RHHVF) trades at 20.8x earnings. Analysts target $470.09 (+14%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RHHVF before investing?
Before investing in Roche Holding AG (RHHVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be made based on individual risk tolerance and financial circumstances.